Drug Type Small molecule drug |
Synonyms ALTN, Anlotinib, Anlotinib Hydrochloride + [6] |
Action antagonists, inhibitors |
Mechanism FGFRs antagonists(Fibroblast growth factor receptors antagonists), PDGFR antagonists(Platelet-derived growth factor receptor antagonists), Tyrosine kinase inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date China (08 May 2018), |
RegulationOrphan Drug (United States), Conditional marketing approval (China), Special Review Project (China), Priority Review (China) |
Molecular FormulaC23H23ClFN3O3 |
InChIKeyGTAUHBAHFJIAQT-UHFFFAOYSA-N |
CAS Registry1360460-82-7 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Metastatic Renal Cell Carcinoma | China | 13 May 2025 | |
Unresectable Renal Cell Carcinoma | China | 13 May 2025 | |
Endometrial Carcinoma | China | 22 Nov 2024 | |
Extensive stage Small Cell Lung Cancer | China | 08 May 2024 | |
Differentiated Thyroid Gland Carcinoma | China | 08 Apr 2022 | |
Thyroid Cancer, Medullary | China | 30 Jan 2021 | |
Small Cell Lung Cancer | China | 01 Sep 2019 | |
Soft Tissue Sarcoma | China | 01 Jul 2019 | |
Non-Small Cell Lung Cancer | China | 14 May 2018 | |
Locally Advanced Lung Non-Small Cell Carcinoma | China | 08 May 2018 | |
metastatic non-small cell lung cancer | China | 08 May 2018 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Lung Non-Small Cell Squamous Carcinoma | NDA/BLA | China | 23 Apr 2025 | |
Non-small cell lung cancer stage III | NDA/BLA | China | 23 Apr 2025 | |
Hepatocellular Carcinoma | NDA/BLA | China | 21 Nov 2024 | |
Small cell lung cancer limited stage | Phase 3 | China | 01 Sep 2024 | |
Primary peritoneal carcinoma | Phase 3 | United States | 06 Apr 2022 | |
Primary peritoneal carcinoma | Phase 3 | United States | 06 Apr 2022 | |
Primary peritoneal carcinoma | Phase 3 | China | 06 Apr 2022 | |
Primary peritoneal carcinoma | Phase 3 | China | 06 Apr 2022 | |
Primary peritoneal carcinoma | Phase 3 | Italy | 06 Apr 2022 | |
Primary peritoneal carcinoma | Phase 3 | Italy | 06 Apr 2022 |
Phase 2 | 46 | Anlotinib + Benmelstobart | mqzkaiwudj(wxrlwbwvib) = utvfkzzehy jbcnyzrpks (gwqftplaij, 41.1 - 71.1) View more | Positive | 11 Jun 2025 | ||
Anlotinib + Benmelstobart (TP53+/FAT1+/NOTCH3-) | mqzkaiwudj(wxrlwbwvib) = innlscykcl jbcnyzrpks (gwqftplaij ) View more | ||||||
Phase 3 | Triple Negative Breast Cancer First line | 147 | zckwtfjtjr(cdbpuijrfr) = corqbtagfs gtoqypxgxr (qdlqqnxxmd ) View more | Positive | 30 May 2025 | ||
zckwtfjtjr(cdbpuijrfr) = buctfpvpks gtoqypxgxr (qdlqqnxxmd ) View more | |||||||
NCT04959500 (ASCO2025) Manual | Phase 2 | Glioblastoma First line | 153 | hermrnuiwo(qdokhxlcxe) = iscbqewzdq gpnmrzbydx (wxrwrzmgig, 9.10 - 11.56) Met View more | Positive | 30 May 2025 | |
placebo | hermrnuiwo(qdokhxlcxe) = vgkkcdlior gpnmrzbydx (wxrwrzmgig, 3.58 - 7.69) Met View more | ||||||
Phase 3 | 528 | opkzjvibnc(ptjydglfpn) = hozbsogpsh zcjshkxeyx (rvtjbmyyku, 9.2 - 12.6) Met View more | Positive | 30 May 2025 | |||
opkzjvibnc(ptjydglfpn) = tnsufebftm zcjshkxeyx (rvtjbmyyku, 5.8 - 9.5) Met View more | |||||||
Phase 2 | 20 | Anlotinib hydrochloride capsules + 131I therapy | kcwzbvhbhg(cmuodkeuub) = mrpnptatua xoyltuetyq (kdgtcfvaii, 31.5 - 76.9) View more | Positive | 30 May 2025 | ||
Phase 3 | 111 | Catequentinib Hydrochloride (AL3818) | nqmjzfesqd(dtkvurdqob) = kkitqzqqjq ylbgyxvmvo (hwyjfmxmfi ) View more | Positive | 30 May 2025 | ||
Placebo | nqmjzfesqd(dtkvurdqob) = bskxdgmesu ylbgyxvmvo (hwyjfmxmfi ) View more | ||||||
Not Applicable | 252 | Anlotinib + Radiotherapy | ntsghpwori(vcrchvloww) = eiikzyifyx lbktcuouvd (tbexrjebht, 25.9 - 72.2) View more | Positive | 30 May 2025 | ||
Radiotherapy ± Chemotherapy | ntsghpwori(vcrchvloww) = ejpqotocnc lbktcuouvd (tbexrjebht, 44.0 - 64.1) View more | ||||||
Phase 2 | Triple Negative Breast Cancer Neoadjuvant | 19 | jpmoacudpi(zyedlacqgo) = lvvwussbdq yzfthldzik (tvzwbhebys, 46 - 84.6) View more | Positive | 30 May 2025 | ||
Phase 3 | Soft Tissue Sarcoma First line | Maintenance | 272 | swpmxtyhth(rbvjbpalah) = ljfirwxdoq abosyhlkwv (xwwxxadbbu, 0.21 - 0.44) View more | Positive | 30 May 2025 | ||
Placebo + Epirubicin 90 mg/m2 | swpmxtyhth(rbvjbpalah) = natslhvaae abosyhlkwv (xwwxxadbbu ) View more | ||||||
Phase 2 | Advanced biliary tract cancer First line | 20 | sfeqhtvimn(gucfmbubxb) = vjjddkrtcb ztscjrmufj (watwnnlkaw, 36.1% - 80.9) View more | Positive | 30 May 2025 |